{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T17:43:31Z","timestamp":1787507011702,"version":"build-2736575974"},"reference-count":40,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmacology"],"published-print":{"date-parts":[[2022,7]]},"DOI":"10.1016\/j.ejphar.2022.175084","type":"journal-article","created":{"date-parts":[[2022,6,6]],"date-time":"2022-06-06T20:01:38Z","timestamp":1654545698000},"page":"175084","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Presenting a bioactive nanotherapeutic agent for colon cancer treatment"],"prefix":"10.1016","volume":"927","author":[{"given":"Parichehr","family":"Hassanzadeh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elham","family":"Arbabi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.ejphar.2022.175084_bib1","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1002\/tox.22268","article-title":"\u2018Inhibition of NF-\u03baB and metastasis in irinotecan (CPT-11)-resistant LoVo colon cancer cells by thymoquinone via JNK and p38","volume":"32","author":"Chen","year":"2017","journal-title":"Environ. Toxicol."},{"issue":"2","key":"10.1016\/j.ejphar.2022.175084_bib2","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1007\/BF02698032","article-title":"\u2018A general review of the role of irinotecan (CPT11) in the treatment of gastric cancer","volume":"24","author":"Farhat","year":"2007","journal-title":"Med. Oncol"},{"issue":"2","key":"10.1016\/j.ejphar.2022.175084_bib3","first-page":"110","article-title":"\u2018Capecitabine plus irinotecan versus 5-FU\/leucovorin plus irinotecan in the treatment of colorectal cancer: a meta-analysis","volume":"13","author":"Guo","year":"2014","journal-title":"Clin. Colorectal Cancer"},{"key":"10.1016\/j.ejphar.2022.175084_bib4","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1038\/sj.bjc.6602403","article-title":"\u2018Antitumour activity of XR5944 in vitro and in vivo in combination with 5-fluorouracil and irinotecan in colon cancer cell lines. Br","volume":"92","author":"Harris","year":"2005","journal-title":"J. Cancer"},{"key":"10.1016\/j.ejphar.2022.175084_bib5","doi-asserted-by":"crossref","first-page":"25","DOI":"10.14748\/bmr.v25.1043","article-title":"\u2018Nanopharmaceuticals: innovative theranostics for the neurological disorders","volume":"25","author":"Hassanzadeh","year":"2014","journal-title":"Biomed. Rev."},{"key":"10.1016\/j.ejphar.2022.175084_bib6","first-page":"167","article-title":"\u2018Carbon nanotubes prolong the regulatory action of nerve growth factor on the endocannabinoid signaling","volume":"19","author":"Hassanzadeh","year":"2015","journal-title":"Physiol. Pharmacol"},{"key":"10.1016\/j.ejphar.2022.175084_bib7","first-page":"37","article-title":"\u2018Creation of nanorobots: both state-of-the-science and state-of-the-art","volume":"27","author":"Hassanzadeh","year":"2016","journal-title":"Biomed. Rev."},{"key":"10.1016\/j.ejphar.2022.175084_bib8","first-page":"25","article-title":"a. \u2018Application of nanostructured lipid carriers: the prolonged protective effects for sesamol in in vitro and in vivo models of ischemic stroke via activation of PI3K signalling pathway. DARU J","volume":"25","author":"Hassanzadeh","year":"2017","journal-title":"Pharmaceut. Sci."},{"key":"10.1016\/j.ejphar.2022.175084_bib9","first-page":"331","article-title":"b. \u2018Aerosol delivery of ferulic acid-loaded nanostructured lipid carriers: a promising treatment approach against the respiratory disorders","volume":"21","author":"Hassanzadeh","year":"2017","journal-title":"Physiol. Pharmacol"},{"key":"10.1016\/j.ejphar.2022.175084_bib10","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.lfs.2016.11.015","article-title":"c. \u2018Application of carbon nanotubes as the carriers of the cannabinoid, 2-arachidonoylglycerol: towards a novel treatment strategy in colitis","volume":"179","author":"Hassanzadeh","year":"2017","journal-title":"Life Sci."},{"key":"10.1016\/j.ejphar.2022.175084_bib11","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.lfs.2016.11.029","article-title":"d. \u2018Nerve growth factor-carbon nanotube complex exerts prolonged protective effects in an in vitro model of ischemic stroke","volume":"179","author":"Hassanzadeh","year":"2017","journal-title":"Life Sci."},{"key":"10.1016\/j.ejphar.2022.175084_bib12","first-page":"26","article-title":"e. \u2018Nanoencapsulation: a promising strategy for biomedical applications of ferulic acid","volume":"28","author":"Hassanzadeh","year":"2017","journal-title":"Biomed. Rev."},{"key":"10.1016\/j.ejphar.2022.175084_bib13","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.lfs.2017.11.046","article-title":"a. \u2018Ferulic acid-loaded nanostructured lipid carriers: a promising nanoformulation against the ischemic neural injuries","volume":"193","author":"Hassanzadeh","year":"2018","journal-title":"Life Sci."},{"key":"10.1016\/j.ejphar.2022.175084_bib14","first-page":"38","article-title":"b. \u2018Carbon nanotubes provide longer lasting gastroprotective effects for anandamide in stress-induced gastric ulcer in rat","volume":"22","author":"Hassanzadeh","year":"2018","journal-title":"Physiol. Pharmacol"},{"key":"10.1016\/j.ejphar.2022.175084_bib15","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.jconrel.2020.08.060","article-title":"\u2018Nanotheranostics against COVID-19: from multivalent to immune-targeted materials","volume":"328","author":"Hassanzadeh","year":"2020","journal-title":"J. Contr. Release"},{"key":"10.1016\/j.ejphar.2022.175084_bib16","first-page":"119128","article-title":"a. \u2018Coating of ferulic acid-loaded silk fibroin nanoparticles with neutrophil membranes","volume":"270","author":"Hassanzadeh","year":"2021","journal-title":"A promising strategy against the acute pancreatitis. Life Sci"},{"key":"10.1016\/j.ejphar.2022.175084_bib17","doi-asserted-by":"crossref","first-page":"119289","DOI":"10.1016\/j.lfs.2021.119289","article-title":"a. \u2018The significance of bioengineered nanoplatforms against SARS-CoV-2: from detection to genome editing","volume":"274","author":"Hassanzadeh","year":"2021","journal-title":"Life Sci."},{"key":"10.1016\/j.ejphar.2022.175084_bib18","doi-asserted-by":"crossref","first-page":"119400","DOI":"10.1016\/j.lfs.2021.119400","article-title":"b. \u2018The biomedical significance of multifunctional nanobiomaterials: the key components for site-specific delivery of therapeutics","volume":"277","author":"Hassanzadeh","year":"2021","journal-title":"Life Sci."},{"key":"10.1016\/j.ejphar.2022.175084_bib19","doi-asserted-by":"crossref","first-page":"119272","DOI":"10.1016\/j.lfs.2021.119272","article-title":"c. \u2018The capabilities of nanoelectronic 2-D materials for bio-inspired computing and drug delivery indicate their significance in modern drug design","author":"Hassanzadeh","year":"2021","journal-title":"Life Sci."},{"key":"10.1016\/j.ejphar.2022.175084_bib20","first-page":"333","article-title":"b. \u2018Lipid-based nanocarriers provide prolonged anticancer activity for palbociclib: In vitro and in vivo evaluations","volume":"59","author":"Hassanzadeh","year":"2021","journal-title":"Acta Med. Iran."},{"key":"10.1016\/j.ejphar.2022.175084_bib21","first-page":"430","article-title":"c. \u2018Development of a biomimetic peptide-based nanoformulation against the breast cancer","volume":"59","author":"Hassanzadeh","year":"2021","journal-title":"Acta Med. Iran."},{"key":"10.1016\/j.ejphar.2022.175084_bib22","first-page":"157","article-title":"\u2018A mechanistic study on altered pharmacokinetics of irinotecan by st. John's Wort. Curr","volume":"8","author":"Hu","year":"2007","journal-title":"Drug Metabol"},{"key":"10.1016\/j.ejphar.2022.175084_bib23","doi-asserted-by":"crossref","first-page":"5920","DOI":"10.3390\/ijms21165920","article-title":"\u2018Ursolic acid-based derivatives as potential anti-cancer agents: an update","volume":"21","author":"Khwaza","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejphar.2022.175084_bib24","doi-asserted-by":"crossref","first-page":"36256","DOI":"10.1039\/C7RA05913B","article-title":"\u2018Self-assembled nanoparticles based on a carboxymethylcellulose\u2013ursolic acid conjugate for anticancer combination therapy","volume":"7","author":"Liu","year":"2017","journal-title":"RSC Adv."},{"key":"10.1016\/j.ejphar.2022.175084_bib25","doi-asserted-by":"crossref","first-page":"103","DOI":"10.2174\/1568009023333890","article-title":"\u2018Pharmacology of Topoisomerase I inhibitors irinotecan (CPT-11) and topotecan","volume":"2","author":"Mathijssen","year":"2002","journal-title":"Curr. Cancer Drug Targets"},{"issue":"7","key":"10.1016\/j.ejphar.2022.175084_bib26","doi-asserted-by":"crossref","first-page":"6458","DOI":"10.1021\/acsnano.8b02881","article-title":"\u2018Quantitative assessment of nanoparticle biodistribution by fluorescence imaging, revisited","volume":"12","author":"Meng","year":"2018","journal-title":"ACS Nano"},{"key":"10.1016\/j.ejphar.2022.175084_bib27","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1007\/s10620-018-5000-0","article-title":"\u2018Precision medicine for CRC patients in the veteran population: state-of-the-art, challenges and research directions","volume":"63","author":"Mohapatra","year":"2018","journal-title":"Dig. Dis. Sci."},{"issue":"134","key":"10.1016\/j.ejphar.2022.175084_bib28","article-title":"\u2018Changes in the renin angiotensin system during the development of colorectal cancer liver metastases","volume":"10","author":"Neo","year":"2010","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ejphar.2022.175084_bib29","volume":"30","author":"Ou","year":"2020","journal-title":"\u2018Nanodrug carrier based on poly(ursolic acid) with self-anticancer activity against colorectal cancer"},{"key":"10.1016\/j.ejphar.2022.175084_bib30","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.3390\/cancers11101581","article-title":"\u2018Synergistic anti-tumor effect of mTOR inhibitors with irinotecan on colon cancer cells","volume":"11","author":"Reita","year":"2019","journal-title":"Cancers"},{"key":"10.1016\/j.ejphar.2022.175084_bib31","first-page":"177","article-title":"\u2018Colorectal cancer statistics. 2017. CA Cancer J","volume":"67","author":"Siegel","year":"2017","journal-title":"Clin"},{"key":"10.1016\/j.ejphar.2022.175084_bib32","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1208\/s12249-013-0028-0","article-title":"\u2018Development and characterization of ursolic acid nanocrystals without stabilizer having improved dissolution rate and in vitro anticancer activity","volume":"15","author":"Song","year":"2014","journal-title":"AAPS PharmSciTech"},{"key":"10.1016\/j.ejphar.2022.175084_bib33","first-page":"3117","article-title":"\u2018Current development of biodegradable polymeric materials for biomedical applications. Drug Des. Devel","volume":"12","author":"Song","year":"2018","journal-title":"Ther"},{"issue":"1","key":"10.1016\/j.ejphar.2022.175084_bib34","first-page":"175","article-title":"\u2018Cytotoxicity to colon cancer cells in vitro is stimulated by pre-incubation with trifluorothymidine. Eur","volume":"43","author":"Temmink","year":"2007","journal-title":"J. Cancer"},{"key":"10.1016\/j.ejphar.2022.175084_bib35","first-page":"303","article-title":"\u2018Active loading liposomal irinotecan hydrochloride: preparation, in vitro and in vivo evaluation. Asian J","volume":"8","author":"Wei","year":"2013","journal-title":"Pharm. Res. (N. Y.)"},{"issue":"11","key":"10.1016\/j.ejphar.2022.175084_bib36","doi-asserted-by":"crossref","first-page":"20614","DOI":"10.3390\/molecules201119721","article-title":"\u2018Ursolic acid- A pentacyclic triterpenoid with a wide spectrum of pharmacological activities","volume":"20","author":"Wo\u017aniak","year":"2015","journal-title":"Molecules"},{"key":"10.1016\/j.ejphar.2022.175084_bib37","doi-asserted-by":"crossref","first-page":"2619","DOI":"10.1038\/bjc.2013.638","article-title":"\u2018A c-Met inhibitor increases the chemosensitivity of cancer stem cells to the irinotecan in gastric carcinoma. Br","volume":"109","author":"Yashiro","year":"2013","journal-title":"J. Cancer"},{"key":"10.1016\/j.ejphar.2022.175084_bib38","doi-asserted-by":"crossref","first-page":"4443","DOI":"10.1021\/acs.molpharmaceut.0c00443","article-title":"Triple strategies to improve oral bioavailability by fabricating coamorphous forms of ursolic acid with piperine: enhancing water-solubility, permeability, and inhibiting Cytochrome P450 Isozymes","volume":"17","author":"Yu","year":"2020","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ejphar.2022.175084_bib39","first-page":"1909","article-title":"\u2018Efficient delivery of ursolic acid by poly(N-vinylpyrrolidone)-block-poly (\u03b5-caprolactone) nanoparticles for inhibiting the growth of hepatocellular carcinoma in vitro and in vivo","volume":"10","author":"Zhang","year":"2015","journal-title":"Int. J. Nanomed."},{"key":"10.1016\/j.ejphar.2022.175084_bib40","first-page":"1","article-title":"\u2018Ursolic acid enhances the therapeutic effects of oxaliplatin in colorectal cancer by inhibition of drug resistance","volume":"1","author":"Zhang","year":"2017","journal-title":"Cancer Sci."}],"container-title":["European Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299922003454?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299922003454?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T23:08:20Z","timestamp":1757977700000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014299922003454"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7]]},"references-count":40,"alternative-id":["S0014299922003454"],"URL":"https:\/\/doi.org\/10.1016\/j.ejphar.2022.175084","relation":{},"ISSN":["0014-2999"],"issn-type":[{"value":"0014-2999","type":"print"}],"subject":[],"published":{"date-parts":[[2022,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Presenting a bioactive nanotherapeutic agent for colon cancer treatment","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejphar.2022.175084","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"175084"}}